) Long term objectives are to synthesize and develop new antiangiogenic compounds. We have synthesized and continue to synthesize novel compounds, which inhibit vascular endothelial growth factor production by human cancer cells and, therefore, are potential inhibitors of tumor angiogenesis. These compounds are not cytotoxic to normal vascular endothelial cells (VECs) and, therefore, unlikely to cause systemic toxicity.
Specific aims of the project are to develop methods to specifically deliver the inhibitor of VEGF synthesis to cancer cells which aberrantly express tissue factor (TF) and test the efficacy against human cancer grown m nude mice. This will be accomplished by coupling the agent to an inhibitor of coagulation factor VIIa, which possesses five times higher affinity for TF than VIIa. We and others found that a malignant phenotype of cancer expresses an increased level of TF and VEGF. TF is a transmembrane receptor for VIIa and the VIIa inhibitor. We have recently demonstrated that the cytoplasmic serine residues of TF mediates a signal transduction pathway for VEGF synthesis in cancer cells. VIIa and VIIa inhibitors are equally internalized within cancer cells by ligand-receptor- mediated endocytosis. Biotin-conjugated VIIa inhibitor specifically binds TF on cancer cells. Therefore, our novel synthetic compounds (molecular weight of 300-400, similar to biotin) linked to VIIa inhibitor are likely to specifically bind to TF. We propose to couple the compounds to VIIa inhibitor and to develop chemical coupling methods which allow proteolytic dissociation of the linkage between the compound and VIIa inhibitor inside the cancer cell.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21CA082995-02
Application #
6377463
Study Section
Special Emphasis Panel (ZCA1-SRRB-3 (J1))
Program Officer
Goldman, Stephen
Project Start
2000-06-01
Project End
2002-05-31
Budget Start
2001-06-01
Budget End
2002-05-31
Support Year
2
Fiscal Year
2001
Total Cost
$121,800
Indirect Cost
Name
Emory University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Zhu, Shijun; Kisiel, Walter; Lu, Yang J et al. (2015) Visualizing cancer and response to therapy in vivo using Cy5.5-labeled factor VIIa and anti-tissue factor antibody. J Drug Target 23:257-65
Zhu, Shijun; Moore, Terry W; Morii, Nao et al. (2014) Synthetic curcumin analog UBS109 inhibits the growth of head and neck squamous cell carcinoma xenografts. Curr Cancer Drug Targets 14:380-93
Zhu, Shijun; Moore, Terry W; Lin, Xiaoqian et al. (2012) Synthetic curcumin analog EF31 inhibits the growth of head and neck squamous cell carcinoma xenografts. Integr Biol (Camb) 4:633-40
Olivera, Anlys; Moore, Terry W; Hu, Fang et al. (2012) Inhibition of the NF-?B signaling pathway by the curcumin analog, 3,5-Bis(2-pyridinylmethylidene)-4-piperidone (EF31): anti-inflammatory and anti-cancer properties. Int Immunopharmacol 12:368-77
Ndungu, John M; Lu, Yang J; Zhu, Shijun et al. (2010) Targeted delivery of paclitaxel to tumor cells: synthesis and in vitro evaluation. J Med Chem 53:3127-32
Sun, Aiming; Lu, Yang J; Hu, Haipeng et al. (2009) Curcumin analog cytotoxicity against breast cancer cells: exploitation of a redox-dependent mechanism. Bioorg Med Chem Lett 19:6627-31
Adams, Brian K; Cai, Jiyang; Armstrong, Jeff et al. (2005) EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanism. Anticancer Drugs 16:263-75
Adams, Brian K; Ferstl, Eva M; Davis, Matthew C et al. (2004) Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents. Bioorg Med Chem 12:3871-83